CORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022
BUFFALO, N.Y., March 14, 2022 (GLOBE NEWSWIRE) — Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2021, on Wednesday, March 16, 2022. Athenex’s management team will host a conference call and live audio webcast at 4:30 p.m. Eastern Time.
Please note the call is being rescheduled from the previously announced date of March 15 at 8:00 a.m. Eastern Time.
To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:
Domestic: (877) 407-0784
International: (201) 689-8560
Passcode: 13726462
The live conference call and replay can also be accessed via audio webcast here and on the Investor Relations section of the Company’s website under “Events and Presentations”, located at http://ir.athenex.com/.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, and (3) Cell therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. For more information, please visit www.athenex.com.
Athenex Contacts
Investors
Daniel Lang, MD
Athenex, Inc.
Email: [email protected]
Caileigh Dougherty
Athenex, Inc.
Email: [email protected]
Disclaimer: This content is distributed by The GlobeNewswire
